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Myostatin is a member of the transforming growth factor beta (TGF-β) superfamily that functions as a negative regulator of
skeletal muscle development and growth. Myostatin blockade therefore oﬀers a strategy for promoting muscle growth in livestock
production without resorting to genetic manipulation. In this report, we examined the eﬀect of myostatin inhibition by plasmid-
mediated delivery of a mutant myostatin propeptide (MProD76A), a natural inhibitor of myostatin, on the growth performance of
mice. A signiﬁcant increase in skeletal muscle mass was observed after a single intramuscular injection of naked plasmid DNA
encoding MProD76A into mice. Enhanced muscle growth occurred because of myoﬁber hypertrophy, but no cardiac muscle
hypertrophy and organomegaly was observed in the mice after myostatin inhibition by plasmid-mediated MProD76A delivery.
These results demonstrate a promising approach to enhancing muscle growth that warrants further investigation in domestic
animals.
1.Introduction
Myostatin is a secreted protein that acts as a negative
regulator of skeletal muscle mass [1]. Myostatin gene
knockout mice have about a doubling of skeletal muscle
weights throughout the body as a result of a combination
of muscle ﬁber hyperplasia and hypertrophy [2]. Nat-
ural mutations of myostatin also cause double-muscling
phenotype in cattle breeds [3–5], Texel sheep [6], dogs
[7], and even humans [8]. These ﬁndings have suggested
that agents capable of inhibiting myostatin activity may
have applications for promoting muscle growth in livestock
production.
To enhance growth performance of animal or livestock,
various molecular strategies and traditional breeding tech-
niques have been developed to regulate myostatin activ-
ity. Myostatin gene knockout mice and dominant-negative
myostatin mice have a dramatic and widespread increase
in skeletal muscle mass [2, 9], and so do transgenic mice
[10]a n dﬁ s h[ 11, 12] expressing higher levels of myostatin
inhibitors. The JA16 neutralizing antibodies against myo-
statin have been shown to be capable of increasing muscle
mass by ≈25% when administered to normal mice [13].
However, all these approaches used in the above studies are
of too high cost, complex and impractical for the widespread
applications in livestock production. Thus, developing a
practical and eﬃcacious strategy that can enhance livestock
muscle growth by regulating myostatin activity becomes an
important issue.
It is well known that the direct injection of plasmid DNA
into muscle is simple, inexpensive, and safe nonviral gene
transfertechniquesinvivo[14].Skeletalmusclecanbetrans-
fectedinvivobydirectplasmidDNAinjection,whereforeign
genescanbeexpressedatsigniﬁcantlevelsforupto19month
[15–18]. These characteristics make plasmid-mediated gene
delivery an excellent candidate for agricultural applica-
tion. In addition, the previous studies have demonstrated
that mutant myostatin propeptide (MProD76A), a natural
inhibitorofmyostatin,causesasigniﬁcantincreaseinmuscle
mass after it was injected into normal mice [19]o rmdx mice
[20].Thus,thecombinationofplasmid-mediatedgenedeliv-
ery techniques and MProD76A may be a promising strategy
that can be widely applied to improve animals or livestock
growth.2 Journal of Biomedicine and Biotechnology
In this report, we investigated the eﬀect of myostatin
inhibition on the growth performance of mice by plasmid-
mediated MProD76A delivery. For increasing transgene
expression, bupivacaine was introduced as adjuvant. The
bupivacainehasbeenshowntoresultina4–80-foldenhance-
ment of plasmid gene expression in mice and rats [21]. A
signiﬁcant increase in body mass was observed after a single
intramuscular injection of plasmid DNA (pCI-MProD76A-
EGFP) into the regenerating quadriceps muscle of mice.
Moreover, we encountered no adverse eﬀects resulting from
plasmid delivery to inhibit myostatin activity.
2.MaterialsandMethods
2.1. Expression Plasmids and DNA Preparation. The mouse
myostatin propeptide cDNA (bases 1-798, GenBank acces-
sionno. NM 010834) wasgeneratedbyreverse-transcription
PCR from Kunming mice muscle tissue. The forward and
reverse primers utilized for myostatin propeptide were: 5 -
GCCACCATGATGCAAAAACTGCAAATGTATG-3 ,5  -
CGGGACCTCTTGGGTGTGTCTGTC-3 . The forward
primer contained Kozak consensus sequence (GCCACC)
at the translation initiation site. The propeptide gene
was then cloned into pMD18-T vector (TaKaRa Biotech,
Dalian) to form the pMD18-MPro. The mutation D76A was
introduced in this plasmid by performing PCR-based site-
directed mutagenesis at nucleotide position 299 (counting
from start codon atg). The mutated propeptide (amino
acids 1–266) was inserted into the Sac I /BamH I sites
of pEGFP-N1 (including a linker before EGFP gene) to
generate MProD76A-EGFP fusion gene, and ultimately the
MProD76A-EGFP fragment was cloned into the Xho I
/Not I sites of pCIneo plasmid (Promega) to form pCI-
MProD76A-EGFP construct (Figure 1). The EGFP gene was
cloned into the XhoI/NotIsites of pCIneo plasmid to form
pCI-EGFP construct as control. Plasmids were ampliﬁed
in Escherichia coli DH 5α and puriﬁed with an EndoFree
Plasmid Giga Kit (Tiangen Biotech Co. Ltd, Beijing, China).
All constructs were subjected to DNA sequence analysis to
verify integrity of the constructs.
2.2. Cell Culture and In Vitro Gene Expression Analysis.
C2C12 myoblasts were seeded 18h prior to transfection at
a density of 7.5 × 104 cells/mL in 6-well dishes (2mL)
in growth medium (DMEM + glutamax containing 10%
FBS and 0.5% gentamycin/ampicillin). C2C12 cells were
tranfected with plasmid DNA (2μg) by using lipofectamine
following the manufacturer’s procedure. After transfection,
the medium was replaced with diﬀerentiation medium
(DMEM containing 5% HS) to allow the cells to diﬀer-
entiate. After 72h diﬀerentiation, cells were incubated in
serum-free medium for an additional 48h. The conditioned
media from each plasmid-transfected C2C12 cells were
harvested and stored at −80◦C until further expression
analysis. The eﬃciency of transfection was estimated by
EGFP ﬂuorescence using an Olympus ﬂuorescent micro-
scope. Conditioned media from plasmid-transfected C2C12
cells were concentrated 15-fold by lyophilization and used
to detect secreted MProD76A-EGFP or EGFP by West-
ern blotting. EGFP polyclonal antibodies raised against
a bacterially expressed EGFP were used in the Western
blotting which was performed as described previously
[22].
2.3. Intramuscular Injection of Plasmid DNA in Mice. All
experiments involving animals were approved by the Animal
Care Committee of Shihezi University. Kunming male mice
(Laboratory animal centre, Xinjiang, China) were housed in
a room controlled for lighting (12-h light, 12-h dark cycle)
and temperature (22 ± 2◦C). The mice were allowed free
access to chow and water. On day −5, 50μl of 0.75% bupi-
vacaine hydrochloride was injected into the left quadriceps
muscle of mice (4 weeks old) [21]. On day 0, the mice were
weighed and allocated to two groups, and the regenerating
quadricepsmusclewasinjectedwith100μgpCI-MProD76A-
EGFP or pCI-EGFP in 100μl PBS. The mice were weighed
onceevery5daysandkilled30dayslater.Epididymalfatpad,
heart,kidney,liver,andindividualmusclesfrombothsidesof
each mouse were carefully dissected, and the average weight
was used for each tissue.
2.4. RT-PCR. The RT-PCR method was used to detect
mRNA expression levels of the MProD76A-EGFP gene
in vivo after intramuscular injection of pCI-MProD76A-
EGFP or pCI-EGFP. The injected quadriceps muscles were
used for total RNA extraction following the manufacturer’s
procedure. cDNA was synthesized with the ThermoScript
RT-PCR system (Invitrogen). The speciﬁc primers used for
detectionofMProD76A-EGFPwereasfollows:5 -ACACCC-
AAGAGGTCCCG-3  and 5 -TTGAAGTCGATGCCCTTC-
3 . The primers for ampliﬁcation of β-actin were as follows:
5 -ATCACTATTGGCAACGAGCG-3  and 5 -ACTCAT-
CGTACTCCTGCTTG-3 . The primers for ampliﬁcation
of EGFP were as follows: 5 -CCCGAAGGCTACGTCCAG-
GAG-3  and 5 -CGATGGGGGTGTTCTGCTGGTA-3 .T h e
primers for ampliﬁcation of endogenous myostatin were
as follows: 5 -TCCGCATACTCATCTTGTGC-3  and 5 -
TGCTCTCACTTCCTTGCCT-3 . The products were cloned
and subjected to sequence analysis.
2.5. MProD76A-EGFP Quantiﬁcation in Serum. Blood sam-
ples were collected every week by retro-orbital puncture
of anesthetized mice. Quantiﬁcation of MProD76A-EGFP
in these samples was essentially performed as described
previously [23], but modiﬁed as follows. A known quantity
of standard EGFP was used to generate standard curves for
ﬂuorescence intensity and protein quantity. The standard
EGFP was suspended in either deionized water or serum
from uninjected mice to evaluate the eﬀects of varying
conditions on ﬂuorescence. The MProD76A-EGFP levels
were quantiﬁed using the standard curve equation from the
known EGFP quantity. The values were normalized by sub-
tractingthe535-nmvaluesoftheuninjectedcontrolsamples.
All EGFP ﬂuorescence intensity assay was performed with a
PerkinElmer Victor3 1420 multilabel counter at 535nm in
counts per second.Journal of Biomedicine and Biotechnology 3
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Figure 1: Schematic illustration representing plasmids used in this study. The mutant myostatin propeptide (MProD76A) gene was cloned
intothepCIneoplasmidcontainingaCMVpromoter,chimericintronandsimianvirus40(SV40)poly(A)sequence.The5  primer(→)and
the 3  primer (←) are in the coding area of MProD76A and EGFP, respectively. A 510-bp band indicated mRNA expression of MProD76A-
EGFP. A 300-bp band indicated mRNA expression of control EGFP.
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Figure 2: Expression of MProD76A-EGFP and EGFP in transiently transfected C2C12 cells. (a) Fluorescent microscopy of C2C12 cells
transfected with pCI-MProD76A-EGFP or pCI-EGFP and untransfected control. (b) Western blot analysis of MProD76A-EGFP or EGFP
secreted into the conditioned media. MG, pCI-MProD76A-EGFP-transfected cells; G, pCI-EGFP-transfected cells.
2.6. Histological and Morphometric Analysis. Cryosections
(8–10μm) of gastrocnemius muscle were prepared from
frozen muscles. Transverse sections of gastrocnemius were
processed for hematoxylin and eosin (H&E) staining. For
morphometric analysis, images were acquired and the mus-
cle ﬁber sizes were measured with Scion Image software.
2.7. Statistical Analysis. All statistical analyses were per-
formed with SPSS statistical software. Values shown in
the ﬁgures are the mean ± SEM. All statistical tests were
considered to be statistically signiﬁcant at P<. 05.
3. Results
3.1. pCI-MProD76A-EGFP and pCI-EGFP Vector Construc-
tion. To obtain a mutant myostatin propeptide that would
have a more robust inhibiton eﬀe c to nm y o s t a t i n[ 19], we
mutated the propeptide at the proteolytic cleavage site by
replacing the aspartate at position 76 with an alanine residue
(D76A). In addition, we fused EGFP to the C terminus
of the mutant propeptide to monitor the expression and
secretion of the transgene. This MProD76A-EGFP fusion
construct was inserted into pCIneo vector under control of
the cytomegalovirus (CMV) promoter to obtain the pCI-
MProD76A-EGFP vector (Figure 1). A vector pCI-EGFP was
used as a control.
3.2. Expression of Mutant Propeptide in C2C12 Cells. In vitro
expression of pCI-MProD76A-EGFP or pCI-EGFP was ﬁrst
examined in transiently transfected C2C12 cells by EGFP
ﬂuorescence (Figure 2(a)). After transfection, C2C12 cells
were placed into diﬀerentiation medium for 72h to induce4 Journal of Biomedicine and Biotechnology
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Figure 3: In vivo expression of pCI-MProD76A-EGFP in injected mice. (a) Expression of pCI-MProD76A-EGFP assayed by RT-PCR after
intramuscular injection of pCI-MProD76A-EGFP into the quadriceps muscle of mice. Left panels: RT-PCR bands (510bp) for MProD76A-
EGFP; RT-PCR bands (350bp) for β-actin, which served as an internal control. Right panels: RT-PCR bands for EGFP (300bp) and
endogeous myostatin (460bp). M, DNA markers; C, control muscle; MG, pCI-MProD76A-EGFP-injected muscle; G, pCI-EGFP-injected
muscle. (b) The serum levels of the EGFP protein (ng/mL) in mice injected with pCI-MProD76A-EGFP or pCI-EGFP. The results are
presented as means ± SEM, n = 6.
the cells to diﬀerentiate. The conditioned serum-free media
and cells were harvested after an additional 48h growth in
serum-free medium. The mRNA expression of MProD76A-
EGFP or EGFP was conﬁrmed by RT-PCR in C2C12 cells
transfected with pCI-MProD76A-EGFP or pCI-EGFP (data
not shown).
Secreted MProD76A-EGFP was detected by perform-
ing Western blot analysis of the collected conditioned
media from pCI-MProD76A-EGFP or pCI-EGFP trans-
fected C2C12 cells (Figure 2(b)). MProD76A-EGFP was
successfully detected in the conditioned media from pCI-
MProD76A-EGFP transfected C2C12 cells. EGFP cannot
be secreted into media and therefore not detected in
the conditioned media from pCI-EGFP transfected C2C12
cells. Thus, the skeletal muscle ﬁbers transfected with pCI-
MProD76A-EGFPcanexpressandsecreteMProD76A-EGFP.
3.3. Eﬀect of Mutant Propeptide on Normal Mice. To deter-
mine whether direct injection of plasmid DNA encoding
mutant propeptide into muscle can enhance animal growth,
four-week-old mice were anesthetized and injected with
pCI-MProD76A-EGFP or pCI-EGFP into the regenerat-
ing quadriceps muscle. The in vivo expression of pCI-
MProD76A-EGFPandpCI-EGFPwasconﬁrmedbyRT-PCR
on injected muscle (Figure 3(a)). In addition, we quantiﬁed
EGFP in blood from the injected animals (Figure 3(b)). A
signiﬁcant amount of MProD76A-EGFP was detected in
blood samples from pCI-MProD76A-EGFP injected group,
indicating that the mutant propeptide can be substantially
expressed and secreted into the blood circulation from the
site of muscle injection. However, EGFP is not a secreted
proteinandthereforewasnotdetectedinbloodsamplesfrom
pCI-EGFP injected group.
Mutant propeptide secreted into the blood circulation
after intramuscular injection of pCI-MProD76A-EGFP sig-
niﬁcantly promoted growth throughout the whole body
(Figure 4(a)), as shown by signiﬁcant diﬀerences in body
weight at 30 days (29.83 ± 0.60g versus 26.95 ± 0.35g,Journal of Biomedicine and Biotechnology 5
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Figure 4: Eﬀects of myostatin propeptide delivery on growth performance of mice. (n = 6). Four-week-old mice were injected with pCI-
MProD76A-EGFPorpCI-EGFPintotheregeneratingquadricepsmuscle.(a)MiceinjectedwithpCI-MProD76A-EGFPshowedasigniﬁcant
increase in body mass compared with pCI-EGFP control mice (
∗P <. 05). (b) The mass of individual hindlimb muscles is increased in mice
injected with pCI-MProD76A-EGFP (
∗∗P <. 01;
∗P <. 05). (c) Comparison of the heart, the liver, the kidney, and the epididymal fat pad
weights, no signiﬁcant diﬀerence was found between the two groups.
P<. 05) after injection of pCI-MProD76A-EGFP or pCI-
EGFP. We also dissected and weighed the epididymal fat pad,
the heart, the kidney, the liver, and the individual muscles
including the quadriceps (Quadri), gastrocnemius (Gas),
tibialis anterior (TA) at the end point of the experiment.
All the examined skeletal muscles (TA, Gas, Quadri, and
Diaph) showed a signiﬁcant increase in muscle mass for
pCI-MProD76A-EGFP injected group (Figure 4(b)). The
quadriceps muscle, which showed the greatest increase
among the muscles examined, displayed a 31.58% increase
in muscle mass over the control group (P<. 01). However,
the weights of the epididymal fat pad, the heart, the kidney,
and the liver did not show signiﬁcant diﬀerence between the
two groups (Figure 4(c)).
To determine whether the increase in muscle mass
resulted from hypertrophy or hyperplasia, we performed
histological and morphometric analysis of gastrocnemius
muscle. H&E staining showed larger myoﬁber sizes in the
pCI-MProD76A-EGFP injected mice (Figure 5(a)). Digital
morphometric analysis of 300 myoﬁbers from each of
three mice injected with pCI-MProD76A-EGFP revealed a
signiﬁcant increase in myoﬁber diameter compared with
control mice (Figure 5(b)). The diameter of 77% pCI-
MProD76A-EGFP treated myoﬁbers was measured at 30–
60μm, whereas that of 86% control myoﬁbers was measured
at 15–45μm. There was a shift in muscle size toward bigger
myoﬁber diameter range. But no signiﬁcant diﬀerence was
found in the total muscle myoﬁber numbers per transverse
sections between the two groups (data not shown). These
results suggested that increased muscle mass was due to
hypertrophy rather than hyperplasia.
4. Disscussion
The study on myostatin function has raised the possibility
thatmyostatininhibitionmaybeusefulforincreasingmuscle
mass for agricultural applications. In this regard, inhibition
of endogenous myostatin has been shown to have beneﬁcial6 Journal of Biomedicine and Biotechnology
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Figure 5: Morphometric analysis of gastrocnemius muscle. (a)
H&E staining displays myoﬁber hypertrophy in muscles injected
with pCI-MProD76A-EGFP compared with pCI-EGFP control,
Scale bars: 100μm. (b) Distribution of muscle ﬁber sizes in mice
injected with either pCI-MProD76A-EGFP or pCI-EGFP. The
diameter of 77% pCI-MProD76A-EGFP treated myoﬁbers was
measured at 30–60μm, whereas that of 86% control myoﬁbers was
measured at 15–45μm(
∗P <. 05, n = 3).
eﬀects on the animal growth performance, such as by
intraperitoneal injections of recombinant myostatin binding
proteins into mice [4,24], orvarious ﬁsh [25] and producing
transgenic animals expressing higher levels of myostatin
inhibitors[9–12].However,limitationsofusingrecombinant
myostatinbindingproteinsarethehighcostoftheseproteins
and the requirement for frequent administration (1-2 times
per week) of intraperitoneal injections. The transgenic
animal-based strategy is involved in the genetic alteration
of genome and is not practical for livestock breeding and
production. Using plasmid-mediated delivery of myostatin
inhibitor, it might be possible to inhibit animal endogenous
myostatin in a much simpler and less expensive manner than
other strategies.
We tested the inhibition of myostatin by plasmid-
mediated expression of a mutant propeptide in normal
mice. A signiﬁcant increase in skeletal muscle mass was
obtained after myostatin inhibition. The increased muscle
masswasfoundintheinjectedhindlimbmusclesandremote
muscles to the injection site. Thus, the mutant propeptide
produced in injected muscle was secreted into the blood
circulation, enhancing muscle growth throughout the whole
body. However, when inhibition of myostatin by mutant
propeptide is long-term occurrence in the whole body, there
are still some concern that immune response and adverse
eﬀects on gonadal function and meat quality may be caused
by the mutant propeptide. Additional experiments would be
needed to explore these before the widespread use of such
strategy.
We further revealed that the increase in muscle mass
with MProD76A plasmid injection was the result of muscle
ﬁber hypertrophy and not hyperplasia. This ﬁnding dif-
fers from observations of myostatin gene knockout mice
and MstnD76A/D76A mice, which had both hypertrophy and
hyperplasia [2, 26]. Conversely, neutralizing antibodies to
myostatin causes signiﬁcant increases in muscle mass when
administered to adult mice, and this increase in muscle
growthappearstoresultfrommuscleﬁberhypertrophy[13].
Thus, the development of hyperplasia versus hypertrophy is
likely to be dependent on the time during embryonic devel-
opment or postnatal life at which myostatin activity is lost
[1]. It is noteworthy that systemic myostatin inhibition did
not cause cardiac muscle hypertrophy despite skeletal muscle
hypertrophy, suggesting that cardiac muscle hypertrophy
may not be a concern for application of plasmid-mediated
delivery of myostatin propeptide. In addition, we did not
observe a signiﬁcant diﬀerence in epididymal fat pad mass
after myostatin inhibition. This result diﬀers from the results
reported in the previous papers where fat accumulation
is decreased in the absence of myostatin [27, 28]. This
discrepancy could be due to diﬀerences in loss of myostatin
expression during development and adulthood [13].
In this study, EGFP was fused with MProD76A to
monitor the expression and secretion of transgene. But an
immune response may be elicited in the injected animal,
which potentially lowers the expression of transgene. It is
likely that further optimization of our vector system will be
necessary for practical application. Wolfman have reported
that the propeptide fused with IgG Fc domain may prolong
its half-life of circulation in vivo [19]. Amino acids mutation
of the propeptide that are known to be sites for diﬀerent
peptidases could also prolong its half-life of circulation in
vivo. In addition, synthetic muscle-speciﬁc promoter and
genedeliverytechniquelikeelectroporationhavebeenshown
to eﬀectively increase the utility for delivery of therapeutic
proteins in pig [29, 30]a n dd o g[ 31]. These methods
would improve gene expression and transfection eﬃciency
of plasmid DNA encoding MProD76A when applied in farm
animal.
Insummary,ourstudieshavedemonstratedtheeﬀective-
ness of myostatin inhibition by plasmid-mediated delivery
of the mutant myostatin propeptide in mice. Moreover, the
low cost, the stability, the possibility of mass production of
plasmid DNA as well as the ease of storage and operation,
allow the development of this strategy not only in livestock
production but also as a potential treatment for human
muscle wasting diseases, including sarcopenia and muscular
dystrophies. However, owing to the larger animal size and
longer growth periods, this strategy still needs further
investigation in large animal models.Journal of Biomedicine and Biotechnology 7
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